In recent years, the research and development (R&D) of gene therapy has been increasingly highlighted, particularly in the field of rare diseases. As of August 4, 2023, a total of 10 rare disease gene therapy drugs have been approved for market in the world. There are 170 drugs in clinical and registration phases overseas, 46 drugs in clinical stages in China, and most of which are in early clinical phases. The indications covered by gene therapy drugs developed overseas are broader, while drugs developed locally in China have relatively concentrated indications. Biotech companies are the primary R&D enterprises of gene therapy for rare diseases, and many large MNC companies have entered this field through collaboration and acquisition. Currently, there are almost no large and medium-sized companies in China engaged in the R&D of gene therapy for rare diseases. With the development of innovative gene therapy-related technologies and support from relevant regulations, gene therapy will attract increasing attention from Chinese companies in the future. This article analyzed the gene therapy drugs that were currently approved and under development in the world for treating rare diseases to understand the R&D status of gene therapy for rare diseases drugs in China and abroad.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |